MedTrace Logo

Observation of the Use of QUTENZA™ in Standard Clinical Practice

NCT01737294 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 429

Last updated 2014-10-06

No results posted yet for this study

Summary

This non-interventional study will evaluate the efficacy, tolerability, health related quality of life and use of health resources associated with QUTENZA treatment when QUTENZA is used in standard clinical practice.

The patient's primary diagnosis of peripheral neuropathic pain (PNP) will be classified into subtypes: post-herpetic neuralgia (PHN); HIV-associated neuropathy (HIV-AN); neuropathic back pain; cancer-related neuropathic pain; post-operative \& post-traumatic neuropathic pain; and 'other' neuropathies.

Conditions

  • Peripheral Neuropathic Pain

Interventions

DRUG

Qutenza exposure

Cutaneous patch

Sponsors & Collaborators

  • Astellas Pharma Europe Ltd.

    lead INDUSTRY

Principal Investigators

  • Company Medical Expert · Astellas Pharma Europe Ltd.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • Austria
  • Greece
  • Italy
  • Portugal
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01737294 on ClinicalTrials.gov